Stanley C. Gill

8.9k total citations · 2 hit papers
40 papers, 7.2k citations indexed

About

Stanley C. Gill is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Stanley C. Gill has authored 40 papers receiving a total of 7.2k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 11 papers in Hematology and 10 papers in Oncology. Recurrent topics in Stanley C. Gill's work include Acute Myeloid Leukemia Research (10 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Advanced biosensing and bioanalysis techniques (6 papers). Stanley C. Gill is often cited by papers focused on Acute Myeloid Leukemia Research (10 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Advanced biosensing and bioanalysis techniques (6 papers). Stanley C. Gill collaborates with scholars based in United States, Japan and Canada. Stanley C. Gill's co-authors include Peter H. von Hippel, Barry Polisky, Arthur Pardi, Robert Jenison, Nebojša Janjić, Louis S. Green, Yun Lin, Sumedha D. Jayasena, James A. Farmer and Daniel W. Drolet and has published in prestigious journals such as Science, Nucleic Acids Research and Journal of Clinical Oncology.

In The Last Decade

Stanley C. Gill

36 papers receiving 7.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Calculation of protein extinction coefficients from amino acid sequence data

1989 4.7k citations Stanley C. Gill, Peter H. von Hippel Analytical Biochemistry profile →
High-Resolution Molecular Discrimination by RNA

1994 929 citations Robert Jenison, Stanley C. Gill et al. Science profile →

Peers

Countries citing papers authored by Stanley C. Gill

Since Specialization

Citations

This map shows the geographic impact of Stanley C. Gill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stanley C. Gill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stanley C. Gill more than expected).

Fields of papers citing papers by Stanley C. Gill

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stanley C. Gill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stanley C. Gill. The network helps show where Stanley C. Gill may publish in the future.

Co-authorship network of co-authors of Stanley C. Gill

This figure shows the co-authorship network connecting the top 25 collaborators of Stanley C. Gill. A scholar is included among the top collaborators of Stanley C. Gill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stanley C. Gill. Stanley C. Gill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase 1 evaluation of ASP3082, a first-in-class selective protein degrader, in patients (pts) with KRAS G12D -mutant pancreatic ductal adenocarcinoma (PDAC): Pharmacokinetics (PK) and biomarker insights. 2026 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), (unknown), (unknown), Anthony W. Tolcher, (unknown), Antoine Hollebecque, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Stanley C. Gill, Takeshi Saito, (unknown), (unknown), (unknown), Shigehisa Kitano	0
2	Safety, tolerability, and pharmacokinetics of ASP1235 in relapsed or refractory acute myeloid leukemia: A phase 1 study 2025 ·Leukemia Research ·Monzr M. Al Malki, (unknown), Elizabeth Rich, Jason E. Hill, Stanley C. Gill, (unknown), (unknown), Amir T. Fathi, Maher Abdul‐Hay	2
3	Maintenance therapy with the FMS‐like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS‐like tyrosine kinase 3–internal tandem duplication acute myeloid leukemia: A phase 2 study 2025 ·Cancer ·Emmanuel Gyan, (unknown), (unknown), Alessandro Rambaldi, Gunnar Juliusson, Martin Jädersten, Richard Kelly, (unknown), Wensheng He, Stanley C. Gill, Jason E. Hill, (unknown), David Delgado‐Gómez, Nahla Hasabou	2
4	A phase 1/2 study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia 2024 ·International Journal of Hematology ·(unknown), Toshihiro Miyamoto, Hee‐Je Kim, Yasushi Hiramatsu, June‐Won Cheong, Takayuki Ikezoe, Tomoki Naoe, Koichi Akashi, Satoshi Morita, (unknown), (unknown), (unknown), Takeshi Kadokura, Jason E. Hill, Shuichi Miyawaki, Stanley C. Gill, Alexandra N. Heinloth, Nahla Hasabou	0
5	608O Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC) 2024 ·Annals of Oncology ·Wungki Park, Anup Kasi, Alexander I. Spira, Jordan Berlin, (unknown), (unknown), Yuko Kuboki, Shigehisa Kitano, (unknown), (unknown), (unknown), Soichiro Kondo, (unknown), Hisaki Fujii, Heon‐Jeong Lee, Stanley C. Gill, Abdel Saci, (unknown), Anthony W. Tolcher	15
6	Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML 2023 ·Journal of Clinical Oncology ·Keith W. Pratz, Mohamad Cherry, Jessica K. Altman, Brenda Cooper, Nikolai A. Podoltsev, José C. Cruz, Tara L. Lin, Gary J. Schiller, Joseph G. Jurcic, Adam Asch, (unknown), Jason E. Hill, Stanley C. Gill, (unknown), Elizabeth Rich, Nahla Hasabou, Alexander E. Perl, Mark J. Levis	27
7	Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy 2021 ·Blood ·Eunice S. Wang, Pau Montesinos, Mark D. Minden, Je‐Hwan Lee, Michael Heuser, Tomoki Naoe, Wen‐Chien Chou, Kamel Laribi, Jordi Esteve, Jessica K. Altman, Violaine Havelange, Anne-Marie Watson, Elżbieta Patkowska, Shufang Liu, (unknown), (unknown), Jason E. Hill, Stanley C. Gill, Elizabeth Rich, Ramón V. Tiu	16
8	Effect of Intermittent Dosing Regimens of Erlotinib on Methylnitrosourea-Induced Mammary Carcinogenesis 2013 ·Cancer Prevention Research ·Ronald A. Lubet, Éva Szabó, Kenneth K. Iwata, Stanley C. Gill, Chris Tucker, Ann M. Bode, Vernon E. Steele, M. Margaret Juliana, Holly L. Nicastro, Clinton J. Grubbs	11
9	Pharmacokinetics and Safety of an Anti-Vascular Endothelial Growth Factor Aptamer (NX1838) Following Injection into the Vitreous Humor of Rhesus Monkeys 2000 ·Pharmaceutical Research ·Daniel W. Drolet, J. Arly Nelson, (unknown), Philip M. Zack, (unknown), (unknown), (unknown), James A. Farmer, Julie Wolf, Stanley C. Gill, Raymond A. Bendele	159
10	Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan. 2000 ·PubMed ·David L. Emerson, Raymond A. Bendele, Eric Brown, (unknown), John Desjardins, (unknown), Stanley C. Gill, Marta Hamilton, (unknown), L Moon-McDermott, (unknown), Frank C. Richardson, Blake Tomkinson, Michael J. Luzzio, David P. Baccanari	51
11	Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor 1995 ·Chemistry & Biology ·Louis S. Green, Derek Jellinek, Carol Bell, (unknown), (unknown), Stanley C. Gill, Fiona M. Jucker, Nebojša Janjić	211
12	High-Resolution Molecular Discrimination by RNA breakdown → 1994 ·Science ·Robert Jenison, Stanley C. Gill, Arthur Pardi, Barry Polisky	929
13	Peptide—urea interactions as observed in diketopiperazine—urea cocrystal 1993 ·Biophysical Chemistry ·M.M. Thayer, R. Curtis Haltiwanger, Viloya S. Allured, Stanley C. Gill, Stanley J. Gill	25
14	Urea—diketopiperazine interactions: A model for urea induced denaturation of proteins 1993 ·Biophysical Chemistry ·(unknown), (unknown), Stanley C. Gill	23
15	7 Quantitative Aspects of the Transcription Cycle in Escherichia coli 1992 ·Cold Spring Harbor Monograph Archive ·Peter H. von Hippel, Thomas D. Yager, Stanley C. Gill	5
16	Physical properties of the Escherichia coli transcription termination factor rho. 1. Association states and geometry of the rho hexamer 1992 ·Biochemistry ·Johannes Geiselmann, Thomas D. Yager, Stanley C. Gill, P. Calmettes, Peter H. von Hippel	64
17	Escherichia coli σ70 and NusA proteins 1991 ·Journal of Molecular Biology ·Stanley C. Gill, Thomas D. Yager, Peter H. von Hippel	18
18	Escherichia coli σ70 and NusA proteins 1991 ·Journal of Molecular Biology ·Stanley C. Gill, (unknown), Peter H. von Hippel	108
19	Thermodynamic analysis of the transcription cycle in E. coli 1990 ·Biophysical Chemistry ·Stanley C. Gill, Thomas D. Yager, Peter H. von Hippel	14
20	Calculation of protein extinction coefficients from amino acid sequence data breakdown → 1989 ·Analytical Biochemistry ·Stanley C. Gill, Peter H. von Hippel	4701

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact